

Claims:

1. A purified polypeptide comprising
the amino acid sequence of SEQ ID NO: 2;
an amino acid sequence that differs from SEQ ID NO: 2 by one or more
5 conservative amino acid substitutions; or
an amino acid sequence that differs from SEQ ID NO: 2 by a single mutation,
wherein the single mutation represents a single amino acid deletion, insertion or
substitution.
2. A purified or recombinant polypeptide comprising an amino acid
10 sequence of SEQ ID NO: 2.
3. A nucleic acid sequence comprising the sequence of SEQ ID NO: 1.
4. A transgenic host cell comprising the nucleotide sequence of claim 3.
5. A nucleic acid sequence comprising a 100 bp nucleic acid sequence
that is identical to a contiguous 100 bp sequence of SEQ ID NO: 1.
- 15 6. A method of screening for potential human therapeutic agents, said
method comprising contacting a C7/8 polypeptide with a candidate compound; and
determining if the candidate compound selectively binds to the C7/8 polypeptide.
7. The method of claim 6 wherein the C7/8 polypeptide is expressed on
the surface of a cell.
- 20 8. An antibody that binds specifically to the protein of SEQ ID NO: 2.
9. An antigenic composition comprising a C7/8 polypeptide and a
pharmaceutically acceptable carrier.
10. A purified polypeptide comprising
the amino acid sequence of SEQ ID NO: 9;
25 an amino acid sequence that differs from SEQ ID NO: 9 by one or more
conservative amino acid substitutions; or
an amino acid sequence that differs from SEQ ID NO: 9 by a single mutation,
wherein the single mutation represents a single amino acid deletion, insertion or
substitution.
- 30 11. A purified or recombinant polypeptide comprising an amino acid of
SEQ ID NO: 9.
12. A nucleic acid sequence comprising the sequence of SEQ ID NO: 8.

13. A transgenic host cell comprising the nucleotide sequence of claim 12.
14. A nucleic acid sequence comprising a 100 bp nucleic acid sequence that is identical to a contiguous 100 bp sequence of SEQ ID NO: 8.
15. A method of screening for potential human therapeutic agents, said
5 method comprising contacting a SAMP32 polypeptide with a candidate compound; and determining if the candidate compound selectively binds to the SAMP32 polypeptide.
16. The method of claim 15 wherein the SAMP32 polypeptide is expressed on the surface of a cell.
- 10 17. An antibody that binds specifically to the protein of SEQ ID NO: 9.
18. An antigenic composition comprising a SAMP32 polypeptide and a pharmaceutically acceptable carrier.
19. A purified polypeptide comprising
the amino acid sequence of SEQ ID NO: 16;
15 an amino acid sequence that differs from SEQ ID NO: 16 by one or more conservative amino acid substitutions; or
an amino acid sequence that differs from SEQ ID NO: 16 by a single mutation, wherein the single mutation represents a single amino acid deletion, insertion or substitution.
- 20 20. A purified or recombinant polypeptide wherein said polypeptide comprises an amino acid sequence of SEQ ID NO: 16.
21. A nucleic acid sequence comprising a sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 18.
22. The nucleic acid sequence of claim 21 comprising the SEQ ID NO: 18.
- 25 23. A transgenic host cell comprising the nucleotide sequence of claim 21.
24. A nucleic acid sequence comprising a 100 bp nucleic acid sequence that is identical to a contiguous 100 bp sequence of SEQ ID NO: 14.
25. A method of screening for potential human therapeutic agents, said method comprising contacting a C58 polypeptide with a candidate compound; and
30 determining if the candidate compound selectively binds to the C58 polypeptide.
26. The method of claim 25 wherein the C58 polypeptide is expressed on the surface of a cell.

27. An antibody that binds specifically to the protein of SEQ ID NO: 16.
28. The antibody of claim 27 wherein the antibody binds to amino acids 22-112 of SEQ ID NO: 16.
29. An antigenic composition comprising a C58 polypeptide and a
5 pharmaceutically acceptable carrier.